Traditional left ventricular indices outperform novel cardiovascular magnetic resonance-derived left atrial parameters in predicting adverse left ventricular remodelling after ST-segment elevation myocardial infarction.

Int J CardiolMay 25, 2026 (epub)
Clinical ResearchCardiology

B Yosofi, J M Zelis, A Raafs et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed 200 patients with anterior ST-segment elevation myocardial infarction (STEMI) to evaluate the prognostic significance of left ventricular (LV) global longitudinal strain (GLS), left atrial (LA) strain, and left atrioventricular coupling index (LACI) in predicting adverse LV remodelling. LV GLS was identified as the strongest predictor of adverse remodelling, with an odds ratio of 1.162.

Key findings

  • LV GLS was the strongest predictor of adverse LV remodelling with an odds ratio of 1.162.
  • The significance of LV GLS remained after adjusting for clinical risk factors (OR 1.216).
  • LA strain and LACI did not provide additional prognostic value.
  • LV GLS's prognostic value diminished when adjusted for infarct size and microvascular obstruction.

Why it matters

Understanding which parameters best predict adverse LV remodelling after STEMI can guide clinicians in risk stratification and management decisions, potentially improving patient outcomes.

Source

PubMed · PMID 42190763

Published in Int J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.